57 results
8-K
EX-99.1
RZLT
Rezolute Inc
25 Apr 24
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
5:23pm
drug designation in the European Union for the treatment of Insulinoma, the primary cause of ICTH.
About Rezolute, Inc.
Rezolute strives to disrupt
8-K
EX-99.1
RZLT
Rezolute Inc
11 Mar 24
Regulation FD Disclosure
5:03pm
). RZ358 received Orphan Drug Designation in the United States and European Union for the treatment of congenital HI, as well as Orphan Drug Designation … Drug Designation status in the European Union for the treatment of Insulinoma, the primary cause of ICTH.
About Rezolute, Inc.
Rezolute strives
8-K
EX-99.1
RZLT
Rezolute Inc
29 Jan 24
Unregistered Sales of Equity Securities
5:15pm
Drug Designation in the United States and European Union for the treatment of congenital HI, as well as Pediatric Rare Disease Designation in the U.S
8-K
EX-99.2
198cuu9
14 Dec 23
Plans to report topline data mid-second quarter 2024
4:01pm
8-K
EX-99
cfwa7pt5qx0my
18 Oct 23
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
4:30pm
8-K
EX-99
9no1 np5ygo87
13 Oct 23
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
4:47pm
8-K
EX-99.1
rxrtde2q
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm
8-K
ual izbtqu
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm
8-K
EX-10.2
s28pbli x46
4 May 22
Rezolute, Inc. Announces Closing of Registered Direct Offering
5:20pm
8-K
EX-10.3
eloiv2gepfxk oelzpf
4 May 22
Rezolute, Inc. Announces Closing of Registered Direct Offering
5:20pm
8-K
EX-1.1
uddvax9
4 May 22
Rezolute, Inc. Announces Closing of Registered Direct Offering
5:20pm
424B5
ljwgf o0d
2 May 22
Prospectus supplement for primary offering
6:08am